Vivos Therapeutics, Inc.
VVOSNASDAQHealthcare● Active
$0.87
+$0.01(+0.64%)
Market Cap$5123882
P/E Ratio—
52W High$7.95
52W Low$0.545
Vivos Therapeutics, Inc. (VVOS) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
VVOS · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 20, 2026EPS Actual
-$0.52
Est. -$0.45 · -15.6%
Revenue
$0.01B
Est. $0.00B · +18.2%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 20, 2026
After Market Close
▼ Miss EPS▲ Beat Revenue
VVOS reports quarterly as a NASDAQ-listed Medical - Devices company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.09
Rev. $41.31B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.09
Rev. Est.$41.31B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 18, 2026 | -$0.37 | — | — | — | $0.01B | — |
| ▼ Q2 FY2026 | May 20, 2026 | -$0.45 | -$0.52 | -15.6% | $0.01B | $0.00B | +18.2% |
| ▼ Q2 FY2026 | Apr 15, 2026 | -$0.49 | -$0.58 | -17.2% | $0.00B | $0.01B | -46.1% |
| ▲ Q4 FY2025 | Nov 19, 2025 | -$0.53 | -$0.49 | +7.5% | $0.01B | $0.01B | -4.4% |
| ▼ Q3 FY2025 | Aug 19, 2025 | -$0.27 | -$0.55 | -103.7% | $0.00B | $0.00B | +4.6% |
| ▼ Q2 FY2025 | May 15, 2025 | -$0.44 | -$0.45 | -2.3% | $0.00B | $0.00B | -17.7% |
| ▲ Q1 FY2025 | Mar 31, 2025 | -$0.43 | -$0.28 | +34.9% | $0.00B | $0.00B | -4.8% |
| ▲ Q4 FY2024 | Nov 14, 2024 | -$0.70 | -$0.40 | +42.9% | $0.00B | $0.00B | -0.7% |
Q3 FY2026
Aug 18, 2026
EPS Actual
—
EPS Est.
-$0.37
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 20, 2026Miss
EPS Actual
-$0.52
EPS Est.
-$0.45
EPS Surpr.
-15.6%
Revenue
$0.01B
Q2 FY2026
Apr 15, 2026Miss
EPS Actual
-$0.58
EPS Est.
-$0.49
EPS Surpr.
-17.2%
Revenue
$0.00B
Q4 FY2025
Nov 19, 2025Beat
EPS Actual
-$0.49
EPS Est.
-$0.53
EPS Surpr.
+7.5%
Revenue
$0.01B
Q3 FY2025
Aug 19, 2025Miss
EPS Actual
-$0.55
EPS Est.
-$0.27
EPS Surpr.
-103.7%
Revenue
$0.00B
Q2 FY2025
May 15, 2025Miss
EPS Actual
-$0.45
EPS Est.
-$0.44
EPS Surpr.
-2.3%
Revenue
$0.00B
Q1 FY2025
Mar 31, 2025Beat
EPS Actual
-$0.28
EPS Est.
-$0.43
EPS Surpr.
+34.9%
Revenue
$0.00B
Q4 FY2024
Nov 14, 2024Beat
EPS Actual
-$0.40
EPS Est.
-$0.70
EPS Surpr.
+42.9%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.56 | $-0.53 | $-0.50 | 1 |
| Q3 FY2027 | $-0.56 | $-0.53 | $-0.50 | 1 |
| Q2 FY2027 | $-0.58 | $-0.55 | $-0.52 | 1 |
| Q1 FY2027 | $-0.60 | $-0.57 | $-0.54 | 1 |
| Q4 FY2026 | $-0.27 | $-0.25 | $-0.24 | 1 |
| Q3 FY2026 | $-0.37 | $-0.31 | $-0.26 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 20, 2026 | -15.6% | $0.59 | $0.59 | +0.84% |
| ▼ Q2 FY2026 | Apr 15, 2026 | -17.2% | $1.35 | $1.47 | +8.89% |
| ▲ Q4 FY2025 | Nov 19, 2025 | +7.5% | $2.47 | $2.36 | -4.45% |
| ▼ Q3 FY2025 | Aug 19, 2025 | -103.7% | $4.45 | $4.27 | -4.04% |
| ▼ Q2 FY2025 | May 15, 2025 | -2.3% | $3.04 | $3.06 | +0.66% |
| ▲ Q1 FY2025 | Mar 31, 2025 | +34.9% | $3.11 | $2.85 | -8.36% |
| ▲ Q4 FY2024 | Nov 14, 2024 | +42.9% | $3.12 | $3.12 | +0.00% |
| ▲ Q3 FY2024 | Aug 14, 2024 | +42.9% | $2.30 | $2.37 | +3.04% |
Q2 FY2026+0.84%
Report Date
May 20, 2026
EPS Beat/Miss
-15.6%
Price Before
$0.59
Price After
$0.59
Q2 FY2026+8.89%
Report Date
Apr 15, 2026
EPS Beat/Miss
-17.2%
Price Before
$1.35
Price After
$1.47
Q4 FY2025-4.45%
Report Date
Nov 19, 2025
EPS Beat/Miss
+7.5%
Price Before
$2.47
Price After
$2.36
Q3 FY2025-4.04%
Report Date
Aug 19, 2025
EPS Beat/Miss
-103.7%
Price Before
$4.45
Price After
$4.27
Q2 FY2025+0.66%
Report Date
May 15, 2025
EPS Beat/Miss
-2.3%
Price Before
$3.04
Price After
$3.06
Q1 FY2025-8.36%
Report Date
Mar 31, 2025
EPS Beat/Miss
+34.9%
Price Before
$3.11
Price After
$2.85
Q4 FY2024+0.00%
Report Date
Nov 14, 2024
EPS Beat/Miss
+42.9%
Price Before
$3.12
Price After
$3.12
Q3 FY2024+3.04%
Report Date
Aug 14, 2024
EPS Beat/Miss
+42.9%
Price Before
$2.30
Price After
$2.37
Avg Beat Reaction-2.44%
Avg Miss Reaction+1.59%
Beat Rate4 / 8 quarters
Largest Move+8.89% (Q2 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: VVOS ends December
Vivos Therapeutics, Inc. (VVOS) most recently reported earnings on May 20, 2026 for Q2 FY2026, posting EPS of $-0.52 — missing the analyst consensus of $-0.45 by -15.6%. The next VVOS earnings date is expected around September 1, 2026.
Each quarter, investors track VVOS earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. VVOS revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
VVOS's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
VVOS earnings · 5 questionsVivos Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. VVOS typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; VVOS historically reports after market close (AMC).
VVOS earnings datewhen is VVOS earningsVVOS next earnings datewhen does VVOS report earningsVVOS earnings calendar
▸ Source: FMP · Vivos Therapeutics, Inc. SEC filings · US GAAP · Vivos Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026